Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil☆
References (21)
- et al.
Pharmac. Ther.
(1983) - et al.
J. biol. Chem.
(1951) - et al.
J. biol. Chem.
(1964) - et al.
Pharmac. Ther.
(1981) Chem. Biol. Interact.
(1981)- et al.
Pharmacotherapy
(1982) - et al.
J. med. Chem.
(1971)- et al.
Drug Metab. Dispos.
(1979) - et al.
Drug Intell. clin. Pharm.
(1982)
There are more references available in the full text version of this article.
Cited by (142)
DDPH, a novel antihypertensive agent, is a potential dual inhibitor of hepatic CYP2D and CYP3A
2016, Chemico-Biological InteractionsCitation Excerpt :Verapamil strongly inhibited CYP3A4 activity and weakly inhibited CYP2D6 [19,20]. It had been reported to interact with many therapeutic agents, including midazolam, carbamazepine, propranolol and cyclosporine, probably by enzyme inhibition [21,22]. Considering the structural and functional similarity of DDPH with mexiletine and verapamil, we hypothesize DDPH may also modulate the relevant hepatic CYP enzymes.
Drug and hormone effects on Vitamin D metabolism
2011, Vitamin D: Two-Volume SetDrug and hormone effects on vitamin D metabolism
2011, Vitamin DDrug and Hormone Effects on Vitamin D Metabolism
2005, Vitamin DDrug and Hormone Effects on Vitamin D Metabolism
2004, Vitamin D, Second Edition
- ☆
This work was supported by a grant from the New Brunswick Heart Foundation.
Copyright © 1985 Published by Elsevier Inc.